98 related articles for article (PubMed ID: 25707289)
1. Rituximab and glucocorticoids: friends or foes? It is all about timing.
Ma S; Platanias LC
Leuk Lymphoma; 2015; 56(8):2237-8. PubMed ID: 25707289
[No Abstract] [Full Text] [Related]
2. Rituximab-induced early and late signaling have opposite effects on dexamethasone-induced apoptosis in human follicular lymphoma cells.
Adem J; Ropponen A; Eeva J; Eray M; Pelkonen J; Nuutinen U
Leuk Lymphoma; 2015; 56(8):2448-57. PubMed ID: 25563557
[TBL] [Abstract][Full Text] [Related]
3. Rituximab maintenance in follicular lymphoma.
Barr PM
Clin Adv Hematol Oncol; 2015 Mar; 13(3):158-61. PubMed ID: 26352422
[No Abstract] [Full Text] [Related]
4. Differential Expression of Bcl-2 Family Proteins Determines the Sensitivity of Human Follicular Lymphoma Cells to Dexamethasone-mediated and Anti-BCR-mediated Apoptosis.
Adem J; Ropponen A; Eeva J; Eray M; Nuutinen U; Pelkonen J
J Immunother; 2016 Jan; 39(1):8-14. PubMed ID: 26641257
[TBL] [Abstract][Full Text] [Related]
5. Follicular non-Hodgkin's lymphoma with refractory paraneoplastic pemphigus: case report with review of novel treatment modalities.
Rossum MM; Verhaegen NT; Jonkman MF; Mackenzie MA; Koster A; Van Der Valk PG; Span LF
Leuk Lymphoma; 2004 Nov; 45(11):2327-32. PubMed ID: 15512825
[TBL] [Abstract][Full Text] [Related]
6. Follicular lymphoma: in vitro effects of combining lymphokine-activated killer (LAK) cell-induced cytotoxicity and rituximab- and obinutuzumab-dependent cellular cytotoxicity (ADCC) activity.
García-Muñoz R; López-Díaz-de-Cerio A; Feliu J; Panizo A; Giraldo P; Rodríguez-Calvillo M; Grande C; Pena E; Olave M; Panizo C; Inogés S
Immunol Res; 2016 Apr; 64(2):548-57. PubMed ID: 26659089
[TBL] [Abstract][Full Text] [Related]
7. HA14-1, a small molecule Bcl-2 antagonist, induces apoptosis and modulates action of selected anticancer drugs in follicular lymphoma B cells.
Skommer J; Wlodkowic D; Mättö M; Eray M; Pelkonen J
Leuk Res; 2006 Mar; 30(3):322-31. PubMed ID: 16213584
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of PI3-kinase-Akt pathway enhances dexamethasone-induced apoptosis in a human follicular lymphoma cell line.
Nuutinen U; Postila V; Mättö M; Eeva J; Ropponen A; Eray M; Riikonen P; Pelkonen J
Exp Cell Res; 2006 Feb; 312(3):322-30. PubMed ID: 16309671
[TBL] [Abstract][Full Text] [Related]
9. The effect of microenvironmental CD40 signals on TRAIL- and drug-induced apoptosis in follicular lymphoma cells.
Nuutinen U; Ropponen A; Eeva J; Eray M; Pellinen R; Wahlfors J; Pelkonen J
Scand J Immunol; 2009 Dec; 70(6):565-73. PubMed ID: 19906199
[TBL] [Abstract][Full Text] [Related]
10. Quantitative proteomic analysis of follicular lymphoma cells in response to rituximab.
Everton KL; Abbott DR; Crockett DK; Elenitoba-Johnson KS; Lim MS
J Chromatogr B Analyt Technol Biomed Life Sci; 2009 May; 877(13):1335-43. PubMed ID: 19010092
[TBL] [Abstract][Full Text] [Related]
11. Histone deacetylase inhibition as a mechanism for the therapeutic effect of statins (3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors) in follicular lymphoma.
Barker CA; Yahalom J
J Clin Oncol; 2010 Aug; 28(24):e426; author reply e427-8. PubMed ID: 20566995
[No Abstract] [Full Text] [Related]
12. Milatuzumab and veltuzumab induce apoptosis through JNK signalling in an NF-κB dependent human transformed follicular lymphoma cell line.
Smith MR; Jin F; Joshi I
Br J Haematol; 2014 Apr; 165(1):151-3. PubMed ID: 24386925
[No Abstract] [Full Text] [Related]
13. High IL-21 receptor expression and apoptosis induction by IL-21 in follicular lymphoma.
Akamatsu N; Yamada Y; Hasegawa H; Makabe K; Asano R; Kumagai I; Murata K; Imaizumi Y; Tsukasaki K; Tsuruda K; Sugahara K; Atogami S; Yanagihara K; Kamihira S
Cancer Lett; 2007 Oct; 256(2):196-206. PubMed ID: 17624663
[TBL] [Abstract][Full Text] [Related]
14. Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomised, double-blind, parallel-group, phase 3 trial.
Ogura M; Sancho JM; Cho SG; Nakazawa H; Suzumiya J; Tumyan G; Kim JS; Lennard A; Mariz J; Ilyin N; Jurczak W; Lopez Martinez A; Samoilova O; Zhavrid E; Yañez Ruiz E; Trneny M; Popplewell L; Coiffier B; Buske C; Kim WS; Lee SJ; Lee SY; Bae YJ; Kwak LW
Lancet Haematol; 2018 Nov; 5(11):e543-e553. PubMed ID: 30389036
[TBL] [Abstract][Full Text] [Related]
15. PDTC enables type I TRAIL signaling in type II follicular lymphoma cells.
Nuutinen U; Simelius N; Ropponen A; Eeva J; Mättö M; Eray M; Pellinen R; Wahlfors J; Pelkonen J
Leuk Res; 2009 Jun; 33(6):829-36. PubMed ID: 18977530
[TBL] [Abstract][Full Text] [Related]
16. CXCR4 expression during tumour cell death.
Skommer J; Wlodkowic D; Pelkonen J
Leuk Res; 2007 Aug; 31(8):1155-6. PubMed ID: 17064769
[No Abstract] [Full Text] [Related]
17. A review of rituximab, the first anti-CD20 monoclonal antibody used in the treatment of B non-Hodgkin's lymphomas.
Feugier P
Future Oncol; 2015; 11(9):1327-42. PubMed ID: 25952779
[TBL] [Abstract][Full Text] [Related]
18. Signal transducers and activators of transcription 5a-dependent cross-talk between follicular lymphoma cells and tumor microenvironment characterizes a group of patients with improved outcome after R-CHOP.
Taskinen M; Valo E; Karjalainen-Lindsberg ML; Hautaniemi S; Meri S; Leppä S
Clin Cancer Res; 2010 May; 16(9):2615-23. PubMed ID: 20388848
[TBL] [Abstract][Full Text] [Related]
19. Prognostic implications of histologic grade and intensity of Bcl-2 expression in follicular lymphomas undergoing rituximab-containing therapy.
Maeshima AM; Taniguchi H; Nomoto J; Miyamoto K; Fukuhara S; Munakata W; Maruyama D; Kim SW; Watanabe T; Kobayashi Y; Tobinai K; Tsuda H
Hum Pathol; 2013 Nov; 44(11):2529-35. PubMed ID: 23916290
[TBL] [Abstract][Full Text] [Related]
20. T cells in tumors and blood predict outcome in follicular lymphoma treated with rituximab.
Wahlin BE; Sundström C; Holte H; Hagberg H; Erlanson M; Nilsson-Ehle H; Lindén O; Nordström M; Ostenstad B; Geisler CH; Brown Pde N; Lehtinen T; Maisenhölder M; Tierens AM; Sander B; Christensson B; Kimby E
Clin Cancer Res; 2011 Jun; 17(12):4136-44. PubMed ID: 21518780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
